ArticleBiosensors2025
Detection of Exosomal microRNA from Malignant Lung Cells Using a Surface Plasmon Resonance Imaging Biosensor.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The consideration of micro ribonucleic acid (microRNA) molecules is justified by their ability to act as possible biomarkers, which may be used to detect the most prevalent type of lung cancer: non-small-cell lung cancer (NSCLC). This article describes a surface plasmon resonance imaging (SPRi) biosensor, which was considered to detect malignant lung cells using an Au/Ag heterostructure, as well as the DNA tetrahedron framework (DNATF). Considering the Au/Ag heterostructure and the DNATF, the proposed SPRi biosensor was evaluated. Thus, its detection range belongs to the interval 1.82 fM up to 28 nM. The measured limit of detection of this biosensor is 1.55 fM, and the generated images offer sufficient fidelity to conduct a precise medical analysis. Therefore, patients who suffer from NSCLC may be accurately and efficiently determined. The experimental evaluation, which is presented, suggests that this is a biosensor that is capable of optimizing the clinical detection of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.